- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05417516
A Randomized Trial of Five Fraction Partial Breast Irradiation
April 5, 2024 updated by: Ontario Clinical Oncology Group (OCOG)
A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)
The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis.
The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, two-arm, single blinded trial comparing two radiation treatment modalities, PBI and WBI.
Following BCS or on the completion of additional adjuvant chemotherapy, eligible and consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast (without evidence of metastatic disease); with microscopically clear resection margins of 1mm (or no residual disease on re-excision) and negative axillary node involvement will be randomized in a 1:1 fashion to receive either PBI (experimental group) or WBI (control group).
Study participants will receive 26Gy in 5 fractions in both treatment arms, treated once per day, for a period of 5-7 days.
Study participants will not be made aware of treatment allocation to prevent any potential bias in their assessment of cosmesis.
Stratification factors include tumour size, estrogen receptor (ER) status, and clinical centre.
Study Type
Interventional
Enrollment (Estimated)
910
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shelley Chambers, MA
- Phone Number: 905-928-8842
- Email: chamberss@hhsc.ca
Study Contact Backup
- Name: Sharon Nason
- Phone Number: 42622 905-527-2299
- Email: spelleb@mcmaster.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Not yet recruiting
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada
- Not yet recruiting
- Cross Cancer Institute
-
-
British Columbia
-
Lethbridge, British Columbia, Canada
- Not yet recruiting
- Lethbridge Cancer Centre
-
Prince George, British Columbia, Canada
- Not yet recruiting
- BCCA-Centre for the North
-
Victoria, British Columbia, Canada
- Not yet recruiting
- BCCA-Vancouver Island Cancer Centre
-
-
NFLD
-
Saint John's, NFLD, Canada
- Not yet recruiting
- Dr. H. Bliss Murphy Cancer Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Recruiting
- QEII HSC - Nova Scotia Cancer Centre
-
Contact:
- Maureen Nolan
-
Principal Investigator:
- Maureen Nolan
-
Moncton, Nova Scotia, Canada
- Not yet recruiting
- The Vitalite Health Network - Dr. Leon Richard Oncology Centre
-
-
Ontario
-
Barrie, Ontario, Canada
- Recruiting
- Royal Victoria Regional Health Centre
-
Contact:
- Sujata Pokhrel
- Email: pokhrels@rvh.on.ca
-
Contact:
- Christine DiMarco
- Email: dimarcoc@rvh.on.ca
-
Principal Investigator:
- Jessica Conway
-
Hamilton, Ontario, Canada
- Recruiting
- Juravinski Cancer Centre
-
Contact:
- Alyssa Roberts
- Email: robertsal@hhsc.ca
-
Contact:
- Shrishyla Manickam
- Email: manickam@hhsc.ca
-
Principal Investigator:
- Do-Hoon Kim
-
London, Ontario, Canada
- Not yet recruiting
- London Regional Cancer Centre
-
London, Ontario, Canada
- Not yet recruiting
- London Regional Cancer Program
-
Newmarket, Ontario, Canada
- Recruiting
- Stronach (Southlake) Regional Health Centre
-
Contact:
- Rachel Woo
- Email: RWoo@southlake.ca
-
Contact:
- Kendra
- Email: KSinnesael@southlake.ca
-
Principal Investigator:
- Tatiana Conrad
-
Sault-Sainte-Marie, Ontario, Canada
- Not yet recruiting
- Algoma District Cancer Program
-
Thunder Bay, Ontario, Canada
- Not yet recruiting
- Thunder Bay Regional Health Sciences
-
Toronto, Ontario, Canada
- Recruiting
- Princess Margaret Hospital
-
Contact:
- Jemima Macadangdang
- Email: Jemima.Macadangdang@uhn.ca
-
Principal Investigator:
- Jennifer Croke
-
Toronto, Ontario, Canada
- Not yet recruiting
- Toronto-Sunnybrook Regional Cancer Centre
-
-
Quebec
-
Chicoutimi, Quebec, Canada
- Not yet recruiting
- CIUSS du Saguenay-Lac-Saint-Jean
-
Greenfield Park, Quebec, Canada
- Not yet recruiting
- CSSS Champlain - Charles LeMoyne
-
Laval, Quebec, Canada
- Not yet recruiting
- Hopital de la Cite-de-la-Sante
-
Lévis, Quebec, Canada
- Not yet recruiting
- Centre integre de cancerologie de Chaudieres Appalaches
-
Montréal, Quebec, Canada
- Recruiting
- McGill University Health Centre
-
Principal Investigator:
- Tarek Hijal
-
Contact:
- Marianna Perna
- Email: marianna.perna@muhc.mcgill.ca
-
Contact:
- Tatiana Carvalho
- Email: tatana.carvalho@muhc.mcgill.ca
-
Québec, Quebec, Canada
- Recruiting
- CHUQ-Pavillon Hotel-Dieu de Quebec
-
Principal Investigator:
- Valerie Theberge
-
Contact:
- Josee Allard
- Email: Josee.Allard@chudequebec.ca
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Not yet recruiting
- Centre Hospitalier Regional de Trois-Rivieres
-
Principal Investigator:
- Francois Vincent
-
Contact:
- Marie-Eve Caron
- Phone Number: 63238 819-697-3333
- Email: marie-eve_caron_chrtr@ssss.gouv.qc.ca
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada
- Not yet recruiting
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada
- Not yet recruiting
- Saskatoon Cancer Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 120 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
For inclusion in this study, patients must fulfill all of the following criteria:
- Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease.(AJCC TNM Cancer Staging).
- Treated by BCS with microscopically clear resection margins ≥ 1mm for invasive and non-invasive disease or no residual disease on re-excision.
- Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection.
Exclusion Criteria:
Patients who satisfy any of the following exclusion criteria are NOT eligible for this study:
- Age less than 50 years.
- Known to be BRCA 1 and/or BRCA 2 positive.
- Tumour size >3cm in greatest diameter on pathological examination.
- Lobular carcinoma only.
- More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible).
- Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible).
- History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma.
- Known pregnancy or currently lactating.
- Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma).
- Inability to plan the patient for the experimental technique.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Whole Breast Irradiation (WBI)
26 Gy in 5 fractions to the whole breast
|
The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
|
Experimental: Partial Breast Irradiation (PBI)
26 Gy in 5 fractions to the tumour bed with a margin of normal tissue
|
The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Recurrence
Time Frame: Annually for 5 years post-randomization
|
Time from randomization to any evidence of tumour recurrence (invasive and non-invasive) in the treated breast.
|
Annually for 5 years post-randomization
|
Patient Assessment Cosmesis at 3 years
Time Frame: 3 and 5 years post-randomization
|
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System and the UK Patient Reported Outcomes Questions following BCS.
|
3 and 5 years post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant Disease Free Survival (DDSF)
Time Frame: Annually for 5 years post-randomization.
|
Time from randomization to evidence of metastasis involving distant sites (e.g.
bone, liver, lung, or brain).
|
Annually for 5 years post-randomization.
|
Disease Free Survival (DFS)
Time Frame: Annually for 5 years post-randomization.
|
Time from randomization to local recurrence, regional or distant recurrence, contralateral breast cancer, other second cancer, or death.
|
Annually for 5 years post-randomization.
|
Overall Survival
Time Frame: 3 years post-randomizaton.
|
Time from randomization to death of any cause.
|
3 years post-randomizaton.
|
Radiation Toxicity
Time Frame: 2 weeks and 3 months post-radiation treatment, then annually for 5 years post-randomization.
|
Acute (2 weeks and up to 3 months after completing RT) and late toxicity (beyond the 3 months after completing RT) will be assessed by clinical centre personnel using the NCI CTCAE version 5.0.
|
2 weeks and 3 months post-radiation treatment, then annually for 5 years post-randomization.
|
Nurse/Clinical Research Associate assessed cosmesis at 3 and 5 years.
Time Frame: 3 and 5 years post-randomization.
|
A nurse/Clinical Research Associate (CRA) assessment of cosmesis using the EORTC Breast Cosmetic Rating System.
Nurses and CRAs will be training in assessing cosmesis using training slides and guide previously developed for other trials.
|
3 and 5 years post-randomization.
|
Patient Assessed Cosmesis at 5 years.
Time Frame: 5 years post-randomization.
|
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System13,27,42 and the UK Patient Reported Outcomes Questions following BCS.
|
5 years post-randomization.
|
Patient Reported Quality of Life
Time Frame: 2 weeks post-radiation treatment, then at 3 and 5 years post-randomization.
|
Patients will complete the EORTC Breast Cancer Quality of life questionnaire
|
2 weeks post-radiation treatment, then at 3 and 5 years post-randomization.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Timothy Whelan, M.D., Juravinski Cancer Centre and McMaster University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2023
Primary Completion (Estimated)
November 1, 2029
Study Completion (Estimated)
November 1, 2031
Study Registration Dates
First Submitted
June 7, 2022
First Submitted That Met QC Criteria
June 9, 2022
First Posted (Actual)
June 14, 2022
Study Record Updates
Last Update Posted (Actual)
April 8, 2024
Last Update Submitted That Met QC Criteria
April 5, 2024
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCOG-2022-RAPID2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Clinical Research Centre, MalaysiaMinistry of Health, Malaysia; National University of Malaysia; Institute for...Not yet recruitingBreast Neoplasm FemaleMalaysia
-
Peking University Cancer Hospital & InstituteRecruiting
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
University of Rome Tor VergataRecruiting
-
Mario Negri Institute for Pharmacological ResearchRecruiting
-
Peter MacCallum Cancer Centre, AustraliaRecruitingBreast Neoplasm FemaleAustralia
-
Tongji HospitalThe First Affiliated Hospital with Nanjing Medical University; Qilu Hospital... and other collaboratorsNot yet recruitingBreast Neoplasm Female
-
University of CopenhagenUniversity of Southern DenmarkCompleted
-
Mackay Medical CollegeTaipei Veterans General Hospital, TaiwanCompletedBreast Neoplasm Female
Clinical Trials on Whole Breast Irradiation (WBI)
-
Azienda Ospedaliero-Universitaria CareggiCompleted
-
University Hospital HeidelbergRecruitingBreast CancerGermany
-
NSABP Foundation IncNational Cancer Institute (NCI); Radiation Therapy Oncology GroupActive, not recruitingStage II Breast Cancer | Stage IB Breast CancerUnited States, Canada, Israel, Puerto Rico, Korea, Republic of, Japan, Ireland
-
Istituto Clinico HumanitasTerminatedCancer of BreastItaly
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Regione Emilia-RomagnaCompleted
-
Yonsei UniversityRecruiting
-
Danish Breast Cancer Cooperative GroupDanish Cancer Society; Danish Center for Interventional Research in Radiation...Active, not recruitingBreast CarcinomaDenmark
-
Azienda Ospedaliero-Universitaria CareggiCompletedBreast Cancer | Radiotherapy Side EffectItaly
-
National Cancer Institute, EgyptCompleted